Tempest licenses Senlang CAR-T platform, reports Q3 2026 results
Tempest exercised its option for exclusive rights to Senlang's CD7-targeted in vivo CAR-T platform and reported $0.9 million in cash with going concern doubt.
Tempest Therapeutics reported financial results for the quarter ended September 30, 2026, alongside a business update dated November 13, 2026.
The company exercised its option under an agreement with Hebei Senlang Biotechnology Co., Ltd. to obtain an exclusive worldwide license, excluding China, to develop and commercialize Senlang's CD7-targeted lentiviral vector platform and associated in vivo CAR-T candidates.1 The lead asset from that deal, TPST-4903, targets both BCMA and GPRC5D and is being tested in a Phase 1 dose-escalation trial in patients with relapsed or refractory multiple myeloma.1 Tempest said initial data showing encouraging preliminary clinical responses are expected to be presented at an upcoming scientific conference.1
Separately, Tempest's own pipeline includes TPST-4003, a dual-targeting CD19/BCMA in vivo CAR-T candidate that pairs the company's CD7-targeted mRNA/LNP delivery system with its dual-target CAR architecture for broad B-cell depletion.1 This program advanced under a partnership with Hebei Senlang Biotechnology signed in July 2026 to collaborate on development of certain Tempest in vivo CAR-T candidates, including TPST-4003.1 An investigator-initiated trial in China testing TPST-4003 in roughly 10 patients with myasthenia gravis or multiple sclerosis is expected to begin in the fourth quarter of 2026.1
On financing, Tempest closed a private placement in September 2026 involving pre-funded warrants along with Series C and D warrants, generating gross proceeds of approximately $2.5 million, or about $1.8 million net of fees, with up to roughly $5.0 million more possible if the warrants are exercised for cash.1 It also has access to an equity line with Lincoln Park Capital Fund allowing sales of up to $25.0 million in common stock, rising to $50.0 million if fully used, over a 24-month period beginning September 1, 2026; through September 30, 2026 the company had sold 350,000 shares for about $0.3 million.1
Tempest ended the quarter with $0.9 million in cash and cash equivalents, down from $7.7 million at December 31, 2025.1 The company stated that its existing cash is expected to fund operations for less than 12 months from the date its financial statements were available to be issued, and that substantial doubt exists about its ability to continue as a going concern.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.